The U.S. Food and Drug Administration has granted regular approval to treatment with Rubraca (rucaparib) for the treatment of ...

Menopausal hormone therapy (MHT) does not raise breast cancer risk in women with breast cancer gene mutations, while estrogen only MHT leads to reduced risk.

Gilead Sciences has signed an agreement to acquire Repare Therapeutics’ polymerase theta (Polθ) ATPase inhibitor, RP-3467.

This study came out of a multi-institutional collaboration called the BRCA BCY group, which is an international group of centers that are looking retrospectively at patients diagnosed with young-onset ...

The SHARON trial is a phase 1 study testing a new treatment called GO-4 for patients with advanced pancreatic cancer who have ...

Cedars Sinai gets 30M to establish a specialized BRCA cancer center focusing on research, diagnosis, and treatment in Los Angeles.

SAN ANTONIO – Using menopausal hormone therapy (MHT) was not associated with an increased risk of breast cancer in women with inherited mutations in the BRCA1 or BRCA2 genes, according to the results ...

Using menopausal hormone therapy (MHT) was not associated with an increased risk of breast cancer in women with inherited mutations in the BRCA1 or BRCA2 genes, according to the results of a matched ...

The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...

Johnson & Johnson’s sNDA for Akeega gets US FDA approval to treat patients with BRCA2-mutated mCSPC: Horsham, Pennsylvania Wednesday, December 17, 2025, 13:00 Hrs [IST] Johnson ...

Use of MHT following menopause is not associated with an increased risk for breast cancer among BRCA1 and BRCA2 carriers.

Rucaparib received FDA approval for BRCA-mutated mCRPC after prior androgen receptor–directed therapy, based on the TRITON3 trial results. The trial demonstrated significant improvement in ...